Title : Treatment with yttrium 90 ibritumomab tiuxetan at early relapse is safe and effective in patients with previously treated B-cell non-Hodgkin's lymphoma.

Pub. Date : 2006 Apr

PMID : 16690521






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Yttrium 90 ((90)Y) ibritumomab tiuxetan (Zevalin), a radiolabeled monoclonal antibody against the CD20 antigen, is indicated for the treatment of patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin"s lymphoma (NHL), including patients with rituximab-refractory follicular NHL. Yttrium-90 membrane spanning 4-domains A1 Homo sapiens